Combining cognitive therapy and pharmacotherapy for schizophrenia

Journal of Cognitive Psychotherapy

Volumn 21, Issue 1, 2007, Pages 28-36

  Kingdon, David ^a   Rathod, Shanaya ^b   Hansen, Lars ^a   Naeem, Farook ^a   Wright, Jesse H ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Hampshire Partnership Trust   (United Kingdom)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Cognitive theraphy; Pharmacotherapy; Psychosis; Schizophrenia

Indexed keywords

AMISULPRIDE; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABIS; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LYSERGIDE; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; THIOXANTHENE DERIVATIVE; ZIPRASIDONE;

ADULT; CASE REPORT; COGNITIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LEUKOPENIA; MALE; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TREMOR; WEIGHT GAIN;

EID: 33947528015     PISSN: 08898391     EISSN: None     Source Type: Journal    
DOI: 10.1891/088983907780493278     Document Type: Review

References (35)

1. Amador, X., Flaum, M., Andreasen, N., Strauss, D., Yale, S., Clark, S., et al. (1994). Awareness of illness in schizophrenia and schizoaffective and mood disorders. Archives of General Psychiatry, 51, 826-836.
2. Amador, X., Strauss, D., Yale, S., Flaum, M., Endicott, J., & Gorman, J. (1993). Assessment of insight in psychosis. American Journal of Psychiatry, 150, 873-879.
3. Amador, X. F., Friedman, J. H., Kasapis, C., Yale, S. A., Flaum, M., & Gorman, J. M. (1996). Suicidal behaviour in schizophrenia and its relationship with awareness of illness. American Journal of Psychiatry, 153, 1185-1188.
4. American Psychiatric Association Steering Committee on Practice Guidelines. (2006). American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: Compendium 2006. Washington, DC: American Psychiatric Assocation.
5. Awad, A. G. (2004). Antipsychotic medications: Compliance and attitudes towards treatment. Current Opinion in Psychiatry, 17(2), 75-80.
6. Babiker, I. (1986). Non-compliance in schizophrenia. Psychiatric Developments, 4, 329-337.
7. Beitman B., & Klerman, G. (1991). Integrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Association.
8. Bentinck, C. (1967). Opinions about mental illness held by clients and relatives. Family Process, 6, 193-207.
9. Birchwood, M., & Iqbal, Z. (1998). Depression and suicidal thinking in psychosis: A cognitive approach. In T. Wykes, N. Tarrier, & S. Lewis (Eds.), Outcomes and innovation in psychological treatment of schizophrenia (pp. 81-100). New York: John Wiley.
10. Buchanan, A. (1996). Compliance with treatment in schizophrenia. London: Psychology Press.
11. Carvajal, C. (2004). Poor response to treatment: Beyond medication. Dialogues in Clinical Neuroscience, 6(1), 93-103.
12. Chadwick, P., Birchwood, M., & Trower, P. (1996). Cognitive therapy of voices, delusions and paranoia. Chichester, UK: Wiley.
13. Cookson, J., Taylor, D., & Katona, C. (2002). Use of drugs in psychiatry (5th ed., pp. 307-326). London: Gaskill.
14. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P., for the National Schizophrenia Guideline Development Group. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal, 321, 1371-1376.
15. Green, J. (1998). Frequent rehospitalisation and non-compliance with treatment. Hospital and Community Psychiatry, 39, 963-966.
16. Hayward, P., Chan, N., Kemp, R., Youle, S., & David, A. (1995). Medication self-management: A preliminary report on an intervention to improve medication compliance. Journal of Mental Health, 4(5), 511-519.
17. Johnson, S., & Orrell, M. (1995). Insight and psychosis: A social perspective. Psychological Medicine, 25, 515-520.
18. Kemp, R., Hayward, P., Applewhaite, G., Everitt, B., & David, A. (1996) Compliance therapy in psychotic clients: A randomized controlled trial. British Medical Journal, 312, 345-349.
19. Kingdon, D., Gibson, A., Turkington, D., Rathod, S., & Morrison, A. (in press). Acceptable terminology and subgroups in schizophrenia: An exploratory study. Social Psychiatry and Psychiatric Epidemiology.
20. Kingdon, D. G., & Turkington, D. (1998) Cognitive behaviour therapy: Styles, groups and outcomes. In T. Wykes, N. Tarrier, & S. Lewis (Eds.), Outcome and innovation in the psychological treatment of schizophrenia. Chichester, UK: Wiley.
21. Kingdon, D. G., & Turkington, D. (1994). Cognitive-behavioral therapy of schizophrenia. New York: Guilford.
22. Kingdon, D. G., & Turkington, D. (2002). A casebook guide to cognitive behaviour therapy: Practice, training and implementation. Chichester, UK: Wiley.
23. Kingdon, D. G., & Turkington, D. (2005). Cognitive therapy of schizophrenia. Guide to individualized evidence-based treatment. Series Editor: J. Persons. New York: Guilford.
24. Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., et al. (2004.) The schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin, 30(2), 193-217.
25. Mortimer, A. M. (2004). Novel antipsychotics in schizophrenia. Expert Opinion on Investigational Drugs, 13(4), 315-329.
26. National Institute for Clinical Excellence. (2002). Clinical Guideline 1: Schizophrenia. Retrieved November 14, 2003, from www.nice.org.uk
27. Rathod, S., Kingdon, D., & Turkington, D. (2003). Insight and schizophrenia. Paper presented at the Psychological Interventions in Schizophrenia Conference, Oxford, UK.
28. Renton, C., Affleck, J., Carstairs, G., & Forrest, A. (1963). A follow up of schizophrenic clients in Edinburgh. Acta Psychiatrica Scandinavica, 39, 548-581.
29. Sensky, T., Turkington, D., Kingdon, D., Scott, J., Siddle, R., O'Carroll, M., et al. (2000) A randomized controlled trial of cognitive behavioural therapy for persistent symptoms in schizophrenia resistant to medication. Archives of General Psychiatry, 57, 165-172.
30. Serretti, A., De Ronchi, D., Lorenzi, C., & Berardi, D. (2004). New antipsychotics and schizophrenia: A review on efficacy and side effects. Current Medicinal Chemistry, 11(3), 343-358.
31. Sullivan, G., Burnam, M., Koegel, P., & Hollenberg, J. (2000). Quality of life of the homeless mentally ill: Results from the course of homelessness study. Psychiatric Services, 51, 1135-1141.
32. Van Putten, T. (1974). Why do schizophrenic clients refuse to take their drugs? Archives of General Psychiatry, 31, 67-72.
33. Vaughn, C., & Leff, J. P. (1976). The influence of family and social factors on the course of psychiatric illness. British Journal of Psychiatry, 129, 125-137.
34. Wright, J. H. (2004). Integrating cognitive-behavioral therapy and pharmacotherapy. In R. Leahy (Ed.), Contemporary cognitive therapy: Theory, research, and practice. New York: Guilford Press.
35. Young, J., Zonana, H., & Shepler, L. (1986). Medication non-compliance in schizophrenia: Codification and update. Bulletin of American Academy of Psychiatry and Law, 14, 105-122.